BTIG initiated coverage of Hims & Hers with a Buy rating and $35 price target The firm says its likes Hims & Hers because of its “disruptive” business model approach that delivers health services to members through a non-traditional, direct-to-consumer, cash-pay approach. Demand for the company continues to be high, the home-grown electronic medical record seems comprehensive, and the business is well integrated with its 503A and 503B affiliated pharmacies, the analyst tells investors in a research note. BTIG expects Hims’ revenue growth and demand for obesity health products to remain robust.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HIMS:
- Hims & Hers price target raised to $24 from $21 at Piper Sandler
- BofA says Hims’ semaglutide compounding opportunity may be shorter than expected
- End to tirzepatide shortage has read on Hims GLP-1 trajectory, says Leerink
- Hims & Hers falls after FDA ends shortage of Lilly weight loss drug
- Hims & Hers falls -12.0%
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
